比较TissuePatch™与不使用TissuePatch™封闭胰腺组织表面预防根治性胃切除术后胰瘘的疗效:一项前瞻性单中心随机对照试验的研究方案
这是一项前瞻性、单中心、随机、优效性临床试验,计划纳入154例接受根治性胃切除术的患者,随机分为实验组(77例)使用TissuePatch™封闭胰腺表面和对照组(77例)不使用TissuePatch™。主要终点是根治性胃切除术后胰瘘(POPF)的发生率,次要终点包括术后死亡率、术后住院时间、胰瘘分级、淋巴结清扫数目、术后并发症发生率及TissuePatch™相关并发症发生率。研究假设TissuePatch™可显著降低POPF发生率并改善患者预后。
要点
- TissuePatch™是一种可吸收、合成、易操作的封闭贴片,可有效防止组织表面液体渗漏。
- 试验计划纳入154例,实验组77例使用TissuePatch™封闭胰腺表面,对照组77例不使用。
- 主要终点为根治性胃切除术后胰瘘(POPF)发生率,次要终点包括术后死亡率、住院时间等。
核心结论
- 本试验首次前瞻性随机评估根治性胃切除术中使用TissuePatch™覆盖胰腺被膜创面是否降低POPF发生率。
- 研究者推测TissuePatch™将较不使用组显著降低POPF发生率并改善患者预后。
- 若TissuePatch™较不使用组显著降低POPF发生率并改善围手术期恢复,将被推荐并批准用于未来根治性胃切除术。
研究设计与样本
- 前瞻性、单中心、随机、临床优效性试验,计划纳入154例符合入组标准且不符合排除标准的患者。
- 随机分为实验组(77例)使用TissuePatch™封闭胰腺表面和对照组(77例)不使用TissuePatch™。
- 主要终点为根治性胃切除术后胰瘘(POPF)发生率;次要终点包括术后死亡率、术后住院时间、胰瘘分级、淋巴结清扫数目、术后并发症发生率及TissuePatch™相关并发症(肠粘连、肠梗阻、胰腺实质萎缩、慢性胰腺炎和过敏反应)发生率。
- 本研究经中国临床试验注册伦理委员会批准(ChiECRCT20220165)(V2.0),所有结果将可获取并发表于同行评议期刊。
- 试验注册于ClinicalTrials.gov NCT05404256,注册日期2022年5月20日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为单中心研究,结果需在多中心随机对照临床试验中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic fistula is a common complication after radical gastrectomy that can be fatal in severe cases. Currently, the avoidance of pressure and thermal injury to the pancreas is the main approach to preventing postoperative pancreatic fistula (POPF); however, its incidence still remains high and seriously affects the perioperative rehabilitation of patients. TissuePatch™ is an absorbable, synthetic, and easy-to-operate patch for sealing, which can effectively prevent liquid leakage on the tissue surface. Therefore, we explored whether TissuePatch™ covering the surface of the pancreas could effectively prevent the occurrence of pancreatic fistula after radical gastrectomy or reduce its severity. METHODS: This is a prospective, single-center, randomized, clinical superiority trial. We will enroll 154 patients who meet the inclusion criteria but do not meet the exclusion criteria for this trial and randomly assign them to an experimental group (77) that uses TissuePatch™ to seal the pancreas surface and to a control group (77) that does not use TissuePatch™. The primary endpoint will be the incidence of POPF about radical gastrectomy. The secondary endpoints will be postoperative mortality, length of postoperative hospital stay, classification of pancreatic fistula, number of lymph node dissections, incidence of postoperative complications, and incidence of TissuePatch™-related complications, such as intestinal adhesion, intestinal obstruction, parenchymal atrophy of the pancreas, chronic pancreatitis, and allergic reactions. DISCUSSION: This trial is the first prospective randomized controlled trial to evaluate whether the use of TissuePatch™ to cover pancreatic capsular wound during radical gastrectomy reduces the incidence of POPF. We speculate that TissuePatch™ will significantly reduce the incidence of POPF and improve the prognosis of patients compared with the non-use group. Moreover, the results of the trial will provide a simple and effective new method for the prevention of pancreatic fistula after radical gastrectomy. ETHICS AND DISSEMINATION: This study was approved by the Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20220165) (V2.0). All results of the study will be available and published in peer-reviewed journals. TRIAL REGISTRATION: ClinicalTrials.gov NCT05404256. Registered on May 20, 2022. STRENGTHS AND LIMITATIONS OF THIS STUDY: This is the first prospective randomized controlled trial to evaluate whether the use of TissuePatch™ to seal the pancreatic tissue surface during radical gastrectomy reduces the incidence of POPF. If TissuePatch™ is shown to significantly reduce the incidence of POPF and improve the perioperative recovery of patients compared to the non-use group, it will be recommended and approved for future radical gastrectomy. Compared to other preventive measures, TissuePatch™ is simple and easy to perform and has a short intraoperative time and learning curve. Since this is a single-center study, the results need to be further validated in a multicenter randomized controlled clinical trial.
引用
- Yue C, Mo Z, Yang Q, et al. Comparison of the efficacy of TissuePatch™ versus no TissuePatch™ to seal pancreatic tissue surface for the prevention of pancreatic fistula after radical gastrectomy: study protocol for a prospective, single-center, randomized controlled trial. Trials. 2025. PMID: 41456003. doi:10.1186/s13063-025-09144-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。